Anticalin

Source: Wikipedia, the free encyclopedia.
3D structure model of an anticalin (ribbon) in complex with digitoxigenin (sticks)

Anticalin proteins are artificial

kDa
.

The Anticalin technology is exclusively commercialized by Pieris Pharmaceuticals in Freising, Germany.[1] Anticalin is a registered trademark of Pieris.[citation needed]

Properties

Anticalin proteins have better tissue penetration than antibodies and are stable at temperatures up to 70 °C. Unlike antibodies, they can be produced in bacterial cells like

E. coli in large amounts.[2]

While antibodies can only be directed at macromolecules such as proteins and at small molecules (haptens) only if bound to macromolecules,[3] Anticalin proteins are able to selectively bind to small molecules as well.[citation needed]

They were mainly developed at the

therapeutic applications, including the use for targeted drug delivery, are being aimed at.[4] The underlying technology was nominated for the German Future Prize in 2004.[5]

Structure

Characteristic for Anticalin proteins is their barrel structure formed by eight antiparallel

α-helix
. The main structure of Anticalin proteins is identical to wild type lipocalins. Conformational deviations are primarily located in the four loops reaching in the ligand binding site.
[2] Mutagenesis of amino acids at the binding site allows for changing the affinity and selectivity.[citation needed]

References

  1. ^ "Pieris Pharmaceuticals, Inc". Pieris Pharmaceuticals, Inc. Retrieved 16 June 2015.
  2. ^
    S2CID 19992238
    .
  3. .
  4. ^ Skerra, A (2002). "Anticaline" (PDF). BIOforum (in German). 4/2002. Darmstadt: GIT Verlag: 227–229.[permanent dead link]
  5. ^ "Deutscher Zukunftspreis 2004: Anticaline – Biopharmazeutische Wirkstoffe durch Protein-Design" [German Future Prize 2004: Anticalins – Biopharmaceutical agents by protein design] (in German). Stifterverband für die Deutsche Wissenschaft. Archived from the original on 8 December 2010. Retrieved 6 December 2010.